SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it will release three-year clinical follow-up data on its CE Mark-approved DESyne® Novolimus Eluting Coronary Stent System, and one year clinical and MSCT (Multi Slice Computed Tomography) results for its fully bioresorbable drug-eluting scaffold system, the DESolve™ Bioresorbable Coronary Scaffold, at the 24th annual Transcatheter Cardiovascular Technologies Conference in Miami on Tuesday, October 23.
